ADVANCING PRECLINICAL STUDIES OF DUAL-TARGETED FINE-TUNED IMMUNE-RESTORING (DFIR) CAR-T CELL THERAPY TO ACHIEVE CURES OF HIGH-GRADE SEROUS OVARIAN CANCER

Dana-Farber Cancer Institute, Inc.

Investigators